Why does your value dossier fail the internal payer review even though the clinical data are convincing?
We build global value dossiers in line with the AMCP Format for Formulary Submissions and align them with the assessment logic of payers and HTA reviewers: from evidence synthesis through the value narrative to a regionally adaptable line of argument. The decisive factor is not the volume of data but who reads the dossier. A reviewer tests every efficacy claim against the methodological standard and against the comparator, not against the regulatory message. Writing from that perspective is what gets a dossier through the review that routinely stops marketing-driven submissions.
- Pharma
- Biotech
- MedTech
Overview
What sets a value dossier apart from regulatory documentation?
Dossiers from the payer and reviewer perspective · AMCP Format for Formulary Submissions · ISPOR Good Practices
Last updated: 2026-06-13
A value dossier is not a condensed regulatory dossier but a stand-alone argument for reimbursement. It is addressed to payers, Pharmacy & Therapeutics Committees and HTA reviewers, that is, to audiences with different assessment questions than those of a regulatory authority. These points determine whether the dossier passes the internal review:
- The AMCP Format for Formulary Submissions structures the dossier around the questions of a formulary reviewer: disease burden, product description, clinical evidence against the relevant comparator, health-economic value and budget impact. Every claim must be substantiated and testable against the standard.
- The German benefit assessment under SGB V § 35a (AMNOG) assesses the added benefit relative to the appropriate comparator therapy; a dossier that does not address the comparator cleanly loses the benefit case regardless of the volume of data.
- The HTA Regulation (EU) 2021/2282 introduces the Joint Clinical Assessment at EU level and shifts part of the clinical assessment into a joint procedure; the value narrative must match the methodological rigor required there rather than trying to repair it after the fact.
- For medtech, the evidence base comes from the clinical evaluation under EU 2017/745 (MDR); the value argument must connect to that evidence and must not make claims the clinical evaluation does not support.
- ISPOR Good Practices define the methodological benchmark for evidence synthesis, indirect comparisons and economic modeling; reviewers assess against these standards, not against the plausibility of the message.
Services
How we support you
Global value dossier in the AMCP format
Development of the complete global value dossier along the AMCP Format for Formulary Submissions: disease burden, product profile, clinical evidence against the relevant comparator, economic value and budget impact as a fully referenced, substantiated document.
Evidence synthesis & value story
Systematic preparation of the clinical and economic evidence in line with ISPOR Good Practices and derivation of a value story in which every value claim traces back to a verifiable source and the appropriate comparator.
Reviewer perspective & internal review
Assessment of the dossier from the perspective of a formulary and HTA reviewer: identifying the claims that are vulnerable in review and closing the evidence gaps before submission rather than during the assessment procedure.
Learn more →Regional adaptation & local dossiers
Derivation of local dossiers from the global value dossier for the respective assessment logic, such as the appropriate comparator therapy under SGB V § 35a in Germany, so that the global narrative and the local requirements stay consistent.
Connection to HEOR & modeling
Integration of the health-economic models into the dossier so that budget-impact and cost-benefit claims align with the underlying model assumptions and remain traceable in review.
Learn more →How we work together
What it comes down to
A value dossier rarely fails for lack of data; it fails on the sequence of decisions. Whoever first defines the relevant comparator, that is, the appropriate comparator therapy under SGB V § 35a or the comparator arm expected in the Joint Clinical Assessment under EU 2021/2282, knows which evidence the dossier must carry before the value story is written. Reverse the sequence and write the narrative out of the regulatory message, and you produce a dossier that argues against the wrong comparison and breaks down in the reviewer review at exactly the points where the assessment question was different from the marketing question.
The second bottleneck is the consistency between narrative and model. The AMCP Format for Formulary Submissions requires that clinical value, budget impact and the health-economic model come from a single set of assumptions; if the running text diverges from the underlying model, the inconsistency devalues both parts at once. That is why we start at the beginning, with the comparator and evidence gaps first, then the narrative, then the model integration, so that the internal review confirms the claims instead of striking them. For medtech, the argument stays tied to the clinical evaluation under EU 2017/745 (MDR), so that the dossier claims no benefit the evidence does not cover.
Our approach
Our approach
Step
Result
Evidence & comparator review
Inventory of the available clinical and economic evidence, a defined relevant comparator and documented evidence gaps before writing begins.
Value narrative & dossier architecture
A structured argument along the AMCP format: every value claim mapped to a source and a chapter.
Evidence synthesis & model integration
Evidence prepared in line with ISPOR Good Practices, consistently linked to the HEOR models.
Internal reviewer review
A dossier assessed from the payer and HTA reviewer perspective, with a list of vulnerable claims and closed gaps.
Global value dossier finalized
An approved global value dossier with a fully substantiated line of argument.
Regional adaptation
Local dossiers for the respective assessment procedures, consistent with the global narrative.
Common pitfalls
Where projects commonly fail
The dossier is written out of the regulatory and marketing message instead of the reviewer's assessment question.
A formulary or HTA reviewer tests every efficacy claim against the methodological standard and against the comparator. Claims that do not survive this scrutiny cost credibility for the entire dossier.
The relevant comparator is bypassed.
The benefit assessment under SGB V § 35a evaluates the added benefit relative to the appropriate comparator therapy; a dossier that argues against placebo or an unaccepted comparator arm misses the case regardless of data quality.
The value story and the health-economic model drift apart.
When the budget impact in the running text relies on assumptions different from the underlying model, the inconsistency surfaces in review and devalues both components. The dossier and the model must come from a single set of assumptions.
The global value dossier is built without regional adaptability.
The assessment logic of AMNOG, NICE or the Joint Clinical Assessment under EU 2021/2282 differs in comparator, endpoints and evidence requirements; a global dossier without a clean adaptation layer creates breaks at every local submission.
For medtech, the dossier claims a benefit that the clinical evaluation under EU 2017/745 (MDR) does not support.
Value claims that go beyond the substantiated clinical evidence are removed by the payer review, which weakens the remaining argument.
FAQ
Frequently asked questions
Sources
- AMCP Format for Formulary Submissions: Academy of Managed Care Pharmacy
- ISPOR Good Practices for Outcomes Research: methodological guidelines for evidence synthesis and modeling
- SGB V § 35a: benefit assessment of medicinal products with new active substances (AMNOG)
- Regulation (EU) 2021/2282 on health technology assessment (HTA Regulation)
- Regulation (EU) 2017/745 (MDR): clinical evaluation as the evidence base in medtech
- https://theentourage.de/expertise/value-dossier/ (existing page content, revised)
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Case Studies
What this looks like in practice
Regulations & standards considered
- AMCP Format for Formulary Submissions (Academy of Managed Care Pharmacy)
- ISPOR Good Practices for Outcomes Research (evidence synthesis & modeling)
- SGB V § 35a (benefit assessment of medicinal products, AMNOG)
- Regulation (EU) 2021/2282 (HTA Regulation, Joint Clinical Assessment)
- EU 2017/745 (MDR): clinical evaluation as the evidence base for medtech dossiers
Related topics
HTA Dossier →
The specific submission for AMNOG, NICE and the Joint Clinical Assessment
HEOR & Health Economics →
The health-economic models behind the value claims
Real-World Evidence →
Post-market evidence that supports the dossier beyond RCT data
Market Access Strategy →
The strategic frame across comparator, evidence and reimbursement
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.de
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences